 Suzanne Fiorillo
Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 6 | 2025 | 75 | 0.890 |
Why?
| | HIV Infections | 10 | 2024 | 2696 | 0.620 |
Why?
| | HIV Seropositivity | 2 | 2021 | 118 | 0.550 |
Why?
| | Q Fever | 1 | 2013 | 5 | 0.430 |
Why?
| | Mycoses | 1 | 2013 | 70 | 0.410 |
Why?
| | Herpesvirus 8, Human | 5 | 2021 | 61 | 0.410 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 162 | 0.400 |
Why?
| | Pneumococcal Infections | 1 | 2013 | 110 | 0.390 |
Why?
| | Fever | 1 | 2013 | 301 | 0.380 |
Why?
| | Sexual Behavior | 3 | 2018 | 453 | 0.380 |
Why?
| | Counseling | 1 | 2012 | 382 | 0.310 |
Why?
| | Anti-Retroviral Agents | 3 | 2024 | 229 | 0.300 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2021 | 124 | 0.280 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 389 | 0.260 |
Why?
| | alpha 1-Antichymotrypsin | 1 | 2025 | 4 | 0.240 |
Why?
| | Mass Screening | 1 | 2012 | 1121 | 0.230 |
Why?
| | Gastrointestinal Microbiome | 2 | 2024 | 635 | 0.220 |
Why?
| | Anti-HIV Agents | 3 | 2017 | 743 | 0.210 |
Why?
| | Zimbabwe | 6 | 2024 | 54 | 0.210 |
Why?
| | Tanzania | 2 | 2013 | 42 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2021 | 642 | 0.190 |
Why?
| | Lung Neoplasms | 2 | 2025 | 2353 | 0.170 |
Why?
| | Hexosaminidases | 1 | 2019 | 18 | 0.160 |
Why?
| | Prevotella | 1 | 2018 | 14 | 0.160 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 377 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1170 | 0.150 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 468 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2018 | 157 | 0.130 |
Why?
| | Up-Regulation | 1 | 2019 | 848 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 308 | 0.120 |
Why?
| | Herpesviridae Infections | 2 | 2021 | 142 | 0.120 |
Why?
| | International Cooperation | 1 | 2014 | 172 | 0.110 |
Why?
| | Inflammation | 2 | 2024 | 2694 | 0.110 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2017 | 588 | 0.110 |
Why?
| | Adult | 11 | 2025 | 35361 | 0.110 |
Why?
| | Body Composition | 1 | 2017 | 654 | 0.100 |
Why?
| | HIV-1 | 5 | 2021 | 840 | 0.100 |
Why?
| | Middle Aged | 9 | 2025 | 30977 | 0.100 |
Why?
| | HIV Seronegativity | 1 | 2012 | 25 | 0.100 |
Why?
| | DNA, Viral | 2 | 2013 | 380 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2014 | 179 | 0.100 |
Why?
| | Universities | 1 | 2014 | 404 | 0.100 |
Why?
| | Confidentiality | 1 | 2012 | 70 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2013 | 7050 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 985 | 0.090 |
Why?
| | Vitamin D | 1 | 2014 | 384 | 0.090 |
Why?
| | RNA, Viral | 1 | 2014 | 622 | 0.090 |
Why?
| | Male | 12 | 2025 | 63146 | 0.090 |
Why?
| | Sexual Partners | 1 | 2012 | 179 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2010 | 193 | 0.080 |
Why?
| | Female | 11 | 2025 | 68162 | 0.080 |
Why?
| | Risk-Taking | 1 | 2012 | 344 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1435 | 0.080 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2010 | 226 | 0.080 |
Why?
| | Smokers | 2 | 2020 | 135 | 0.080 |
Why?
| | Plasma | 1 | 2010 | 198 | 0.080 |
Why?
| | Incidence | 2 | 2013 | 2634 | 0.080 |
Why?
| | Humans | 16 | 2025 | 128896 | 0.080 |
Why?
| | Biomedical Research | 1 | 2014 | 654 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1967 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1629 | 0.070 |
Why?
| | Prospective Studies | 5 | 2022 | 7060 | 0.070 |
Why?
| | Aged | 4 | 2013 | 22035 | 0.060 |
Why?
| | Lamivudine | 2 | 2017 | 61 | 0.060 |
Why?
| | Zidovudine | 2 | 2017 | 78 | 0.060 |
Why?
| | Adolescent | 3 | 2013 | 20197 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1264 | 0.050 |
Why?
| | Young Adult | 3 | 2019 | 12286 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2017 | 267 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2021 | 181 | 0.050 |
Why?
| | Viral Load | 2 | 2013 | 448 | 0.040 |
Why?
| | Infant | 1 | 2013 | 8994 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 310 | 0.040 |
Why?
| | Survival Analysis | 2 | 2014 | 1282 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1045 | 0.040 |
Why?
| | Child, Preschool | 1 | 2013 | 10457 | 0.040 |
Why?
| | Proteomics | 1 | 2025 | 985 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 349 | 0.040 |
Why?
| | Radiography, Abdominal | 1 | 2017 | 40 | 0.030 |
Why?
| | Benzoxazines | 1 | 2017 | 31 | 0.030 |
Why?
| | Pilot Projects | 2 | 2014 | 1545 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3334 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2017 | 88 | 0.030 |
Why?
| | Alkynes | 1 | 2017 | 53 | 0.030 |
Why?
| | Anthropometry | 1 | 2017 | 205 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 459 | 0.030 |
Why?
| | Emtricitabine | 1 | 2017 | 161 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 327 | 0.030 |
Why?
| | Risk Factors | 3 | 2018 | 9792 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 824 | 0.030 |
Why?
| | Tenofovir | 1 | 2017 | 225 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2021 | 1040 | 0.030 |
Why?
| | Dideoxynucleosides | 1 | 2014 | 20 | 0.030 |
Why?
| | Organizational Objectives | 1 | 2014 | 73 | 0.030 |
Why?
| | Accreditation | 1 | 2014 | 81 | 0.030 |
Why?
| | Organizational Policy | 1 | 2014 | 76 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 3874 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2013 | 38 | 0.030 |
Why?
| | Child | 1 | 2013 | 20824 | 0.030 |
Why?
| | Smoking | 1 | 2020 | 1501 | 0.030 |
Why?
| | United Kingdom | 1 | 2013 | 263 | 0.030 |
Why?
| | Cytokines | 1 | 2020 | 1995 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2668 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1019 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 861 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 155 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2014 | 10239 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 925 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2530 | 0.020 |
Why?
| | Lung | 1 | 2020 | 3925 | 0.020 |
Why?
| | Disease Progression | 1 | 2014 | 2603 | 0.020 |
Why?
| | Urban Population | 1 | 2009 | 436 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5355 | 0.020 |
Why?
| | Comorbidity | 1 | 2009 | 1542 | 0.010 |
Why?
| | United States | 1 | 2014 | 13975 | 0.010 |
Why?
|
|
Fiorillo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|